As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced or unresectable HCC, for possible government financing. The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder feedback and comments from 01 to 16 December 2025.

This health technology was also reviewed against the Philippine Food and Drug Administration (FDA) requirements for authorization, clinical evidence from systematic review with network meta-analysis (SRNMA) of randomized controlled trials (RCTs) and systematic reviews of observational studies, clinical practice guidelines (CPGs) [local and approved by the Department of Health (DOH), such as the DOH Omnibus Health Guidelines (OHG); and/or international, but locally adopted guidelines], and existing recommendations by the World Health Organization (WHO). Further, a costing analysis of this health technology was performed.

As a preliminary recommendation, the HTA Council recommends the following for government financing: (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] as preferred first-line treatment for adults diagnosed with advanced or unresectable HCC; and, (2) Lenvatinib [4 mg/10 mg capsule] as first-line treatment for adults diagnosed with advanced or unresectable HCC who are not candidates for immunotherapy.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the advisory and the evidence document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted for the consideration by the HTA Council, through email at hta@dost.gov.ph. Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please contact us through the same email address.